Bio-Techne reports Q1 adjusted EPS 42c, consensus 38c

Reports Q1 revenue $289.46M, consensus $280.26M. “The start to fiscal 2025 was largely consistent with our expectations, as a high-level of execution by the Bio-Techne (TECH) team drove continued momentum across our Diagnostics & Spatial Biology segment,” said Kim Kelderman, president and CEO of Bio-Techne. “This was augmented by strong results in our cell and gene therapy business, including robust growth in our GMP reagent portfolio. The strength in cell and gene therapy, combined with favorable year-to-date funding dynamics, gives us increased confidence in the forthcoming recovery in our biotech end market.”